ValuEngine cut shares of Biolase, Inc. (NASDAQ:BIOL) from a hold rating to a sell rating in a research report sent to investors on Monday, July 24th.
Separately, Singular Research started coverage on Biolase in a research report on Tuesday, April 25th. They set a buy rating and a $2.50 price target for the company.
Biolase (BIOL) traded up 5.2750% during trading on Monday, reaching $0.8422. The company had a trading volume of 68,808 shares. The company’s 50-day moving average is $0.93 and its 200 day moving average is $1.23. The firm’s market capitalization is $56.98 million. Biolase has a 52 week low of $0.79 and a 52 week high of $1.98.
Biolase (NASDAQ:BIOL) last issued its quarterly earnings data on Wednesday, May 3rd. The medical technology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.03. The business had revenue of $10.87 million during the quarter. Biolase had a negative return on equity of 65.77% and a negative net margin of 29.44%. Equities analysts anticipate that Biolase will post ($0.14) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Biolase, Inc. (NASDAQ:BIOL) Cut to “Sell” at ValuEngine” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/08/06/biolase-inc-nasdaqbiol-downgraded-by-valuengine-updated.html.
A hedge fund recently raised its stake in Biolase stock. Trellus Management Company LLC raised its position in shares of Biolase, Inc. (NASDAQ:BIOL) by 20.3% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 350,857 shares of the medical technology company’s stock after buying an additional 59,104 shares during the period. Trellus Management Company LLC owned 0.52% of Biolase worth $340,000 at the end of the most recent reporting period. 37.58% of the stock is owned by institutional investors.
Biolase Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
